Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

581. Drug treatments for schizophrenia

Drug treatments for schizophrenia Drug treatments for schizophrenia Drug treatments for schizophrenia NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. Drug treatments for schizophrenia. University of York. Effective Health Care 5(6). 1999 Authors' objectives (...) This report summarises the research evidence on drug treatments for schizophrenia. Authors' conclusions Schizophrenia is one of the most common of the severe mental illnesses. Drug treatment with antipsychotics forms the mainstay of effective management, but should be used alongside a range of psychosocial interventions. The newer 'atypical' antipsychotics may be a further refinement, but not a revolution, in the care of those with schizophrenia. They may cause less adverse effects and be more acceptable

1999 Health Technology Assessment (HTA) Database.

582. Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia. Full Text available with Trip Pro

Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia. To investigate whether intensive cognitive behaviour therapy results in significant improvement in positive psychotic symptoms in patients with chronic schizophrenia.Patients with chronic schizophrenia were randomly allocated, stratified according to severity of symptoms and sex, to intensive cognitive behaviour therapy and routine care, supportive counselling and routine care (...) receiving routine care alone also experienced more exacerbations and days spent in hospital.Cognitive behaviour therapy is a potentially useful adjunct treatment in the management of patients with chronic schizophrenia.

1998 BMJ Controlled trial quality: uncertain

583. Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics

Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics Bech P, Peuskens J C, Marder S R, Chouinard G, Hoyberg O J, Huttunen M O, Blin O, Claus A Authors' objectives To assess (...) the benefits and the risks of treating chronic schizophrenia with risperidone or conventional neuroleptics. Searching Not stated. Publication dates of included studies ranged from 1992 to 1995. Study selection Study designs of evaluations included in the review Double-blind randomised controlled trials (RCTs). Follow-up ranged from 4 to 12 weeks. An intention-to-treat (last observation carried forward) analysis was performed. Specific interventions included in the review Risperidone (fixed dosage of 4mg

1998 DARE.

584. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms

interventions included in the review The following antipsychotic and neuroleptic drugs were included: typical antipsychotics including loxapine, haloperidol, thioridazine, and thiothixene; and atypical antipsychotics including clozapine, risperidone, and olanzapine. Some studies allowed antiparkinsonian medications where necessary. Participants included in the review Children and adolescents of both sexes with psychotic disorders including schizophrenia were studied. Schizophrenic patients included those (...) Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms Lewis R Authors' objectives To evaluate the efficacy

1998 DARE.

585. The use of olanzapine as a first and second choice treatment in schizophrenia

The use of olanzapine as a first and second choice treatment in schizophrenia The use of olanzapine as a first and second choice treatment in schizophrenia The use of olanzapine as a first and second choice treatment in schizophrenia Cummins C, Stevens A, Kisely S Authors' objectives To assess whether olanzapine should be used as a first or second choice neuroloeptic, instead of a standard neuroleptic at optimal dose, in the treatment of acute episodes of schizophrenia. The evidence concerning (...) the long-term use of olanzapine was considered, specifically in treatment of acute episodes of schizophrenia as a second choice neuroleptic in cases with poor compliance, non-response or adverse reaction to initial treatment. Searching The electronic databases searched included MEDLINE, Science Citation Index, EMBASE, DARE, Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Register, ISI Conference Proceedings and Transcripts, NHS EED; the search dates were not reported. Handsearches

1998 DARE.

586. Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies

Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies Mojtabai R, Nicholson R A, Carpenter B N Authors' objectives To investigate the role of psychosocial treatments in management of patients (...) with schizophrenia. Specifically, the following questions were addressed: 1. Does the addition of a psychosocial treatment to a standard medical regimen enhance treatment outcome? And if so, what is the magnitude of this added effect? 2. How do different moderators (in particular, modality and orientation) affect the results of psychosocial treatment? 3. How durable are the results of psychosocial treatments? Searching PsycLIT (1974-94) and MEDLINE (1966-94) were searched. In addition, recent issues

1998 DARE.

587. A cost-effectiveness clinical decision analysis model for schizophrenia

of related interest 1. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol. Pharmacoeconomics 1998;13(5 Part 2):575-588. 2. Chouinard G, Albright P S. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology 1997;17(4):298-307. 3. Goldberg D. Cost-effectiveness studies in the treatment of schizophrenia: a review. Schizophrenia Bulletin (...) A cost-effectiveness clinical decision analysis model for schizophrenia A cost-effectiveness clinical decision analysis model for schizophrenia A cost-effectiveness clinical decision analysis model for schizophrenia Palmer C S, Revicki D A, Genduso L A, Hamilton S H, Brown R E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed

1998 NHS Economic Evaluation Database.

588. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia

Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia Rosenheck R, Cramer J, Xu W, Grabowski J, Douyon R, Thomas J, Henderson W, Charney D Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Clozapine use in the treatment of refractory schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with refractory schizophrenia with at least 30-364 days

1998 NHS Economic Evaluation Database.

589. Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study

Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study Sacristan J A, Gomez J C, Martin J, Garcia-Bernardo E, Peralta V, Alvarez E, Gurpegui M Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of the antipsychotic drug olanzapine as a treatmentof refractory schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population 25 patients with treatment refractory

1998 NHS Economic Evaluation Database.

590. The use of olanzapine as a first and second choice treatment in schizophrenia

The use of olanzapine as a first and second choice treatment in schizophrenia The use of olanzapine as a first and second choice treatment in schizophrenia The use of olanzapine as a first and second choice treatment in schizophrenia Cummins C, Stevens A, Kisely S Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Cummins C, Stevens A, Kisely S. The use (...) of olanzapine as a first and second choice treatment in schizophrenia. Birmingham: West Midlands Health Technology Assessment Collaboration (WMHTAC). DPHE Report No. 10. 1998 Authors' objectives To summarise the effectiveness and cost-effectiveness of olanzapine as a first and second choice treatment in schizophrenia. Authors' conclusions Schizophrenia remains a significant health problem despite neuroleptic drugs. Many patients are refractory and others experience significant side effects. Social

1998 Health Technology Assessment (HTA) Database.

591. The use of olanzapine as a first and second choice treatment in schizophrenia

The use of olanzapine as a first and second choice treatment in schizophrenia The use of olanzapine as a first and second choice treatment in schizophrenia The use of olanzapine as a first and second choice treatment in schizophrenia Cummins C, Stevens A, Kisely S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Cummins C, Stevens (...) A, Kisely S. The use of olanzapine as a first and second choice treatment in schizophrenia. Southampton: Wessex Institute for Health Research and Development (WIHRD) (ColLaborative effort with West Midlands Health Technology Assessment ColLaboration, Department of Public Health and Epidemiology) 1998 Authors' objectives The authors assess whether olanzapine should be made available as a first and second line agent for the treatment of all people with schizophrenia. Authors' conclusions The authors

1998 Health Technology Assessment (HTA) Database.

592. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. (Abstract)

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Clozapine, a relatively expensive antipsychotic drug, is widely used to treat patients with refractory schizophrenia. It has a low incidence of extrapyramidal side effects but may cause agranulocytosis. There have been no long-term assessments of its effect on symptoms, social functioning, and the use (...) and cost of health care.We conducted a randomized, one-year, double-blind comparative study of clozapine (in 205 patients) and haloperidol (in 218 patients) at 15 Veterans Affairs medical centers. All participants had refractory schizophrenia and had been hospitalized for the disease for 30 to 364 days in the previous year. All patients received case-management and social-rehabilitation services, as clinically indicated.In the clozapine group, 117 patients (57 percent) continued their assigned

1997 NEJM Controlled trial quality: uncertain

593. [Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia in Spain]

[Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia in Spain] Analisis coste-efectividad de olanzapina frente a haloperidol en el tratamiento de la esquizofrenia en Espana [Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia in Spain] Analisis coste-efectividad de olanzapina frente a haloperidol en el tratamiento de la esquizofrenia en Espana [Cost effectiveness analysis of olanzapine versus haloperidol (...) in the treatment of schizophrenia in Spain] Sacristan J A, Gomez J C, Salvador-Carulla L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of olanzapine, a new drug for the treatment of patients with schizophrenia. Olanzapine has

1997 NHS Economic Evaluation Database.

594. The care of patients with chronic schizophrenia: a comparison between two services

The care of patients with chronic schizophrenia: a comparison between two services The care of patients with chronic schizophrenia: a comparison between two services The care of patients with chronic schizophrenia: a comparison between two services Gater R, Goldberg D, Jackson G, Jennett N, Lowson K, Ratcliffe J, Saraf T, Warner R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Chronic schizophrenia care. Type of intervention Treatment; Health care organisation. Economic study type Cost-effectiveness analysis. Study population Chronic schizophrenia sufferers. The Syndrome Check List (SCL)(Wing et al, 1974)was used to confirm the clinical diagnosis of schizophrenia. Setting The practice setting was both in primary care

1997 NHS Economic Evaluation Database.

595. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol

Status; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Retrospective Studies; Risperidone /adverse effects /economics /therapeutic use; Schizophrenia /drug therapy /economics /physiopathology; Schizophrenic Psychology AccessionNumber 21997001029 Date bibliographic record published 31/03/1999 Date abstract record published 31/03/1999 NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019 University of York Homepage Options Print PubMed (...) Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol Chouinard G, Albright P S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each

1997 NHS Economic Evaluation Database.

596. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia

Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia Glazer W M, Johnstone B M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Antipsychotic therapy. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Schizophrenia, schizophreniform or schizoaffective sufferers. Setting The practice setting was the community. The economic analysis was carried out in the USA. Dates to which data relate Effectiveness and resource date were obtained between 1995 and 1996. 1995 prices were used. Source of effectiveness data Evidence

1997 NHS Economic Evaluation Database.

597. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary

Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary Glennie JL Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Glennie JL. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). 1997 Authors' objectives To carry out a comparative therapeutic and economic evaluation of a) clozapine in treatment-resistantschizophrenic patients or those suffering

1997 Health Technology Assessment (HTA) Database.

598. Sind psychosoziale Interventionen bei schizophrenen Patienten wirksam: eine Metaanalyse [Are psychosocial methods of intervention effective in schizophrenic patients: a meta-analysis]

) or psychopharmacological therapies were also eligible. Participants included in the review Studies with patients with the diagnosis 'schizophrenia' or 'schizo-affective psychosis with schizophrenic emphasis' were eligible for inclusion. Outcomes assessed in the review Outcomes that documented the improvement of patients were eligible for inclusion. These had to be transformable into effect sizes, i.e. reported percentages were not considered. The included studies looked at a range of outcomes: relapse rates, social (...) : The authors stated that further studies on psychosocial interventions for schizophrenia are needed; these should also determine which interventions are successful for which type of patient. Bibliographic details Wunderlich U, Wiedemann G, Buchkremer G. Sind psychosoziale Interventionen bei schizophrenen Patienten wirksam: eine Metaanalyse [Are psychosocial methods of intervention effective in schizophrenic patients: a meta-analysis] Verhaltenstherapie 1996; 6(1): 4-13 Indexing Status Subject indexing

1996 DARE.

599. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety

Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety de Oliveira I R, Miranda-Scippa A M, de Sena E P, Pereira E L, Ribeiro M G, de Castro-e-Silva E, Bacaltchuk J Authors' objectives To compare (...) mg, whilst the dose of haloperidol ranged from 2 to 20 mg. The duration of the treatment ranged from 6 to 12 weeks. Participants included in the review Patients diagnosed as suffering from schizophrenia were included. Outcomes assessed in the review The outcome measures were: the proportion of patients failing to achieve at least a 20% improvement on the positive and negative syndrome scale (PANSS) or brief psychiatric rating scale (BPRS); the proportion of patients discontinuing treatment

1996 DARE.

600. Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: an effect size analysis

standard doses. Searching MEDLINE was searched from 1966 to 1994 using the MeSH terms 'schizophrenia', 'neuroleptic' and 'randomized controlled trial'. Reference lists of review articles and research studies were checked. The search was restricted to English language articles. Study selection Study designs of evaluations included in the review Randomised double-blind controlled trials (RCTs), which randomised schizophrenic patients to standard-dose neuroleptic therapy (i.e. between 200 and 500 mg (...) Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: an effect size analysis Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: an effect size analysis Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: an effect size analysis Barbui C, Saraceno B Authors' objectives To quantify the overall extrapyramidal side-effect improvement in patients treated with low doses of neuroleptics, compared with those receiving

1996 DARE.